The diagnostic, prognostic role and molecular mechanism of miR-328 in human cancer - 08/12/22
, Wenjie Xie , Hongzai Guan ⁎ Abstract |
MicroRNA are non-coding small RNAs that bind to their target mRNA and cause mRNA degradation or translation inhibition. MiRNA dysregulation is linked to a variety of human cancers and has a role in the genesis and development of cancer pathology. MiR-328 has been reported to be involved in various human cancers. And miR-328 is considered a key regulator in human cancer. It participates in biological processes such as proliferation, apoptosis, invasion, migration, and EMT. The present review will combine the basic and clinical studies to find that miR-328 promotes tumorigenesis and metastasis in human cancer. And we will describe the diagnostic, prognostic, and therapeutic value of miR-328 in various human cancers.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abnormal regulation of miR-328 in cancer
Abnormal regulation of miR-328 in cancerga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | MiR-328 is differentially expressed in different types of cancer. |
• | MiR-328 can target multiple different genes to regulate the biological functions of cancer cells. |
• | MiR-328 can be regulated by lncRNAs and circRNAs and participates in multiple signaling pathways. |
• | Targeting miR-328 could be a novel strategy for the diagnosis and treatment of cancer. |
Keywords : MiR-328, Cancer, Biomarker, Mechanism, Tumor suppressor
Plan
Vol 157
Article 114031- janvier 2023 Retour au numéro
Article précédent
- Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
- Jiajia Li, Qingchao Li, Lingyi Zhang, Songling Zhang, Yun Dai
- Circadian clock genes as promising therapeutic targets for bone loss
- Yi Qin, Zhong-hua Chen, Jun-Jie Wu, Zhen-Yu Zhang, Zheng-Dong Yuan, Dan-Yang Guo, Meng-Nan Chen, Xia Li, Feng-Lai Yuan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?